The disappointing performance of SSG/TPI-1 as an anti-cancer agent in both the pre-clinical and clinical studies described above suggests that the adoptive transfer approach of Stromnes et al. [52] might be the most promising avenue for exploitation of SHP-1 inhibition for tumour therapy. Here, NR0B2 is linked to neoplasm.